Ken Griffin Evoke Pharma Inc Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Evoke Pharma Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 11,911 shares of EVOK stock, worth $5,598. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,911Holding current value
$5,598% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding EVOK
# of Institutions
16Shares Held
3.15MCall Options Held
0Put Options Held
0-
Aigh Capital Management LLC Baltimore, MD847KShares$397,8850.16% of portfolio
-
Bleichroeder LP New York, NY825KShares$387,7500.16% of portfolio
-
Altium Capital Management LP New York, NY692KShares$325,4460.19% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT675KShares$317,2500.02% of portfolio
-
Geode Capital Management, LLC Boston, MA49.7KShares$23,3540.0% of portfolio
About Evoke Pharma Inc
- Ticker EVOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 3,343,070
- Market Cap $1.57M
- Description
- Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabeti...